Skip to main content

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

International Journal of Hematology volume 110, pages 559–565 (2019)Cite this article

Abstract

Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety of daratumumab therapy in a real-world setting. Ninety-nine Hungarian patients were included; 48 received monotherapy, while lenalidomide and bortezomib combinations were administered in 29 and 19 cases, respectively. Overall response rate was assessable in 88 patients, with 12 complete, 10 very good partial, 34 partial, and seven minor responses. At a median duration of follow-up of 18.6 months, median progression-free survival (PFS) among all patients was 17.0 months. These values were inferior in the bortezomib combination and monotherapy groups. Patients with early-stage disease (ISS1) had better survival results than those with stage 2 or 3 myeloma (p = 0.009). Heavily pretreated patients had inferior PFS compared to those with 1–3 therapies (p = 0.035). Patients with impaired renal function had PFS results comparable with those having no kidney involvement. There were 10 fatal infections, and the most frequent adverse events were mild infusion-associated reactions and hematologic toxicities. Our results confirm that daratumumab is an effective treatment option for relapsed/refractory MM with an acceptable safety profile in patients with normal and impaired renal function.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Raza S, Safyan RA, Rosenbaum E, Bowman A, Lentzsch S. Optimizing current and emerging therapies in multiple myeloma: a guide for the haematologist. Ther Adv Hematol. 2017;8:55–70.

    CAS  Article  Google Scholar 

  2. Morandi F, Horenstein AL, Costa F, Guiliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol. 2018;9:2722. https://doi.org/10.3389/fimmu.2018.02722 (eCollection).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8.

    Article  Google Scholar 

  4. Van der Weer MS, De Weers M, Van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Hematologica. 2011;96:284–90.

    Article  Google Scholar 

  5. Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, et al. Preclinical evidence for the therapeutic potential of CD28-targeted immune-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21:2802–10.

    CAS  Article  Google Scholar 

  6. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomized, phase 2 trial. Lancet. 2016;387:1551–60.

    CAS  Article  Google Scholar 

  7. Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37–44.

    CAS  Article  Google Scholar 

  8. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.

    CAS  Article  Google Scholar 

  9. Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079–87.

    CAS  Article  Google Scholar 

  10. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

    CAS  Article  Google Scholar 

  11. Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. Haematologica. 2018;103(12):2088–96.

    CAS  Article  Google Scholar 

  12. Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, et al. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected “real-world” population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018. https://doi.org/10.5507/bp.2018.064.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, et al. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Ann Hematol. 2019. https://doi.org/10.1007/s00277-019-03655-5.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubacj JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.

    Article  Google Scholar 

Download references

Funding

No funding is applicable.

Author information

Author notes

  1. Gábor Mikala and László Váróczy equally contributed to this work.

Affiliations

  1. Department of Hematology, Institute for Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98., 4032, Debrecen, Hungary

    Szilvia Lovas, Árpád Illés & László Váróczy

  2. 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

    Gergely Varga, Péter Farkas, Tamás Masszi & Nikolett Wohner

  3. 2nd Department of Internal Medicine and Cardiology Center, Faculty of Medicine, University of Szeged, Szeged, Hungary

    Ágnes Bereczki, Nóra Adamkovich & Zita Borbényi

  4. 1st Department of Internal Medicine, University of Pécs, Pecs, Hungary

    Árpád Szomor & Hussain Alizadeh

  5. National Institute of Oncology, Budapest, Hungary

    Erika Szaleczky, Krisztina Wolf & Tamás Schneider

  6. Department of Hematology, Markusovszky Teaching Hospital, Szombathely, Hungary

    Márk Plander & Tamás Szendrei

  7. Department of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary

    Ottó Csacsovszki, Zoltán Csukly & Gábor Mikala

  8. Department of Hematology, Mór Kaposi Teaching Hospital, Kaposvár, Hungary

    Péter Rajnics & Miklós Egyed

  9. 1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary

    Zsolt Nagy

  10. Department of Hematology, Jósa András Teaching Hospital, Nyíregyháza, Hungary

    László Rejtő

Authors
  1. Szilvia Lovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gergely Varga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Péter Farkas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tamás Masszi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nikolett Wohner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ágnes Bereczki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nóra Adamkovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zita Borbényi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Árpád Szomor
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hussain Alizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Erika Szaleczky
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Krisztina Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tamás Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Márk Plander
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tamás Szendrei
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ottó Csacsovszki
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Zoltán Csukly
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Péter Rajnics
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Miklós Egyed
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Zsolt Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. László Rejtő
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Árpád Illés
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Gábor Mikala
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. László Váróczy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to László Váróczy.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lovas, S., Varga, G., Farkas, P. et al. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. Int J Hematol 110, 559–565 (2019). https://doi.org/10.1007/s12185-019-02715-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02715-w

Keywords

  • Multiple myeloma
  • Daratumumab
  • Treatment response
  • Survival
  • Toxicity